Elicio Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Elicio Therapeutics Stock-Based Compensation Growth & History (ELTX)
Elicio Therapeutics's stock-based compensation was $2.7M for fiscal 2025.
View full Elicio Therapeutics company overviewElicio Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.7M | $1.2M | +85.74% |
| 2024 | 2024-12-31 | $1.5M | $273,000 | +23.16% |
| 2023 | 2023-12-31 | $1.2M | $600,000 | +103.63% |
| 2022 | 2022-12-31 | $579,000 | −$11.5M | −95.19% |
| 2021 | 2021-12-31 | $12.0M | $7.3M | +155.32% |
| 2020 | 2020-12-31 | $4.7M | — | — |
Elicio Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $935,000 | $225,000 | +31.69% |
| Q1 2026 | 2026-03-31 | $868,000 | $351,000 | +67.89% |
| Q4 2025 | 2025-12-31 | $772,000 | $308,000 | +66.38% |
| Q3 2025 | 2025-09-30 | $698,000 | $384,000 | +122.29% |
| Q2 2025 | 2025-06-30 | $710,000 | $360,000 | +102.86% |
| Q1 2025 | 2025-03-31 | $517,000 | $193,000 | +59.57% |
| Q4 2024 | 2024-12-31 | $464,000 | $127,000 | +37.69% |
| Q3 2024 | 2024-09-30 | $314,000 | −$25,000 | −7.37% |
| Q2 2024 | 2024-06-30 | $350,000 | $71,000 | +25.45% |
| Q1 2024 | 2024-03-31 | $324,000 | $100,000 | +44.64% |
| Q4 2023 | 2023-12-31 | $337,000 | $138,000 | +69.35% |
| Q3 2023 | 2023-09-30 | $339,000 | $229,000 | +208.18% |
| Q2 2023 | 2023-06-30 | $279,000 | $40,000 | +16.74% |
| Q1 2023 | 2023-03-31 | $224,000 | $193,000 | +622.58% |
| Q4 2022 | 2022-12-31 | $199,000 | −$1.8M | −90.16% |
| Q3 2022 | 2022-09-30 | $110,000 | −$2.1M | −94.96% |
| Q2 2022 | 2022-06-30 | $239,000 | −$2.5M | −91.21% |
| Q1 2022 | 2022-03-31 | $31,000 | −$5.1M | −99.39% |
| Q4 2021 | 2021-12-31 | $2.0M | $860,000 | +74.01% |
| Q3 2021 | 2021-09-30 | $2.2M | $557,000 | +34.23% |
| Q2 2021 | 2021-06-30 | $2.7M | $1.6M | +148.22% |
| Q1 2021 | 2021-03-31 | $5.1M | $4.3M | +515.02% |
| Q4 2020 | 2020-12-31 | $1.2M | — | — |
| Q3 2020 | 2020-09-30 | $1.6M | — | — |
| Q2 2020 | 2020-06-30 | $1.1M | — | — |
| Q1 2020 | 2020-03-31 | $832,000 | — | — |
Elicio Therapeutics stock-based compensation trends
Over the last five fiscal years, Elicio Therapeutics's stock-based compensation decreased from $4.7M to $2.7M, a change of −$2.0M. The latest reported quarter, Q2 2026, shows $935,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Elicio Therapeutics source filings ↗